Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

4.985 -0.145 (-2.83%)
Streaming Delayed Price Updated: 10:40 AM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and... 
Via StockStory
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls 1%; Uber Sales Miss Estimates ↗
 
Via Benzinga
Topics Earnings
News headline image
Wednesday's session: top gainers and losers ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Myriad Genetics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue... 
Via StockStory
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
1 Unprofitable Stock to Target This Week and 2 to Be Wary Of
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Management will participate in two upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
Study published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews ↗
 
Via Benzinga
News headline image
Myriad Genetics Announces Inducement Awards
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
10 Analysts Assess Myriad Genetics: What You Need To Know ↗
 
Via Benzinga
News headline image
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 per share. This might have investors contemplating their next move. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.